parkinson's%20disease%20-and-%20parkinson's%20disease%20dementia
PARKINSON'S DISEASE & PARKINSON'S DISEASE DEMENTIA

Parkinson's disease is a progressive neurodegenerative disorder that is common, age-related and chronic.

It is caused by loss or degeneration of dopaminergic neurons in the substantia nigra of the midbrain.

Onset of symptoms and progression of the disease is gradual.

Motor signs and symptoms include resting tremor, rigidity, bradykinesia and postural instability.

Parkinson's disease dementia indicates loss of intellectual functions including memory, significant deterioration in the ability to carry out day-to-day activities and changes in social behavior are often noted.

Parkinson's Disease & Parkinson's Disease Dementia References

  1. Ballard C, Ziabreva I, Larsen JP, et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology. 2006 Dec;67(11):1931-1934. PMID: 17159096
  2. Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003 Mar;60(3):387-392. PMID: 12633150
  3. Bronstein JM, Tagliati M, Alterman RL, et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol. 2011 Feb;68(2):165. doi: 10.1001/archneurol.2010.260. Accessed 16 Jun 2011. PMID: 20937936
  4. Fargel M, Grobe B, Oesterle E, et al. Treatment of Parkinson's disease: a survey of patients and neurologists. Clin Drug Investig. 2007;27(3):207-218. PMID: 17305415
  5. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint Task Force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur J Neurol. 2006 Nov;13(11):1186-1202. PMID: 17038032
  6. Lebrun-Frenay C, Borg M. Choosing the right dopamine agonist for patients with Parkinson's disease. Curr Med Res Opin. 2002;18(4):209-214. PMID: 12201621
  7. Lim SY, Fox SH. An update on the management of Parkinson's disease. Geriatr Aging. 2008;11(4):215-222
  8. Miyasaki JM, Martin W, Suchowersky O, et al. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2002 Jan;58(1):011-17. PMID: 11781398
  9. Miyasaki JM, et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006 Apr;66(7):996-1002. PMID: 16606910
  10. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006 Apr;66(7):983-995. PMID: 16606909
  11. Rao SS, et al. Parkinson's disease: diagnosis and treatment. Am Fam Physician. 2006 Dec;74(12):2046-2054. PMID: 17186710
  12. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology. 2001 Jun;56(11)(Suppl 5):S1-S88. PMID: 11402154
  13. Samuel M, Maidment I, Boustani M, Fox C. Clinical management of Parkinson's disease dementia: pitfalls and progress. Adv Psychiatr Treat. 2006;12:121-129
  14. Seppi K, Rascol O. Dementia with Lewy bodies and Parkinson disease with dementia: can MRI make the difference?. Neurology. 2007 Aug;69(8):717-718. PMID: 17709701
  15. Rascol O, Goetz C, Koller W, et al. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet. 2002 May;359(9317):1589-1598. PMID: 12047983
  16. Truong DD, Wolters EC. Recognition and management of Parkinson's disease during the premotor (prodromal) phase. Expert Rev Neurother. 2009 Jun;9(6):847-857. PMID: 19496688
  17. Suchowersky O, et al. Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006 Apr;66:976-982. PMID: 16606908
  18. Suchowersky O, et al. Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006 Apr;66(7):968-975. PMID: 16606907
  19. Young R. Update on Parkinson's disease. Am Fam Physician. 1999 Apr;59(8):2155-2167,2169-2170. PMID: 10221302
  20. Jankovic J, Lang AE. Movement disorders: diagnosis and assessment. In: Bradley W, Daroff R, Fenichel G, et al, eds. Bradley: Neurology in Clinical Practice. 5th ed. Philadelphia: Butterworth Heinemann Elsevier; 2008
  21. MedWormhttp://www.medworm.com/rss/index.php/Neurology/25/http://www.medworm.com/rss/medicalfeeds/specialities/Neurology.xml
  22. Scottish Intercollegiate Guidelines Network. Management of patients with dementia: national clinical guideline. SIGN. http://www.sign.ac.uk. Feb 2006.
  23. National Collaborating Centre for Mental Health, Social Care Institute for Excellence, National Institute for Clinical Excellence. Dementia: a NICE-SCIE guideline on supporting people with dementia and their carers in health and social care. Social Care Institute for Excellence. http://www.scie.org.uk/publications/misc/dementia/dementia-fullguideline.pdf. 2007
  24. Ministry of Health Malaysia, Malaysian Psychiatric Association, Academy of Medicine Malaysia. Malaysian Society of Neurosciences. Clinical practice guidelines: management of dementia. 2nd ed. 2009
  25. Ministry of Health Singapore. Dementia: MOH clinical practice guidelines 3/2007. MOH (Singapore). http://www.moh.gov.sg. 2007
  26. Scottish Intercollegiate Guidelines Network. Diagnosis and pharmacological management of Parkinson's disease. SIGN. http://www.sign.ac.uk/pdf/sign113.pdf. Jan 2010
  27. National Institute of Neurological Disorders and Stroke. Parkinson’s Disease: hope through research. NINDS. http://www.ninds.nih.gov/disorders/parkinsons_disease/detail_parkinsons_disease.htm. 2001
  28. Rodnitzky RL. Parkinson disease dementia. UpToDate. http://www.uptodate.com/contents/parkinson-disease-dementia. Feb 2011. Accessed 09 Sep 2011
  29. National Institute for Health and Care Excellence. Parkinson’s disease: diagnosis and management in primary and secondary care. CG 35. NICE. http://guidance.nice.org.uk/CG35. 2006
  30. Swanberg MM, Kalapatapu RK. Parkinson disease dementia. eMedicine. Jan 2010
  31. Tarsy D. Pharmacologic treatment of Parkinson disease. UpToDate. http://www.uptodate.com/contents/pharmacologic-treatment-of-parkinson-disease. Feb 2011. Accessed 09 Sep 2011
  32. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint Task Force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol. 2006 Nov;13(11):1170-1185. PMID: 17038031
  33. Merino JG. Parkinson disease dementia. eMedicine. http://www.emedicine.com/med/topic3110.htm. 13 Oct 2004. Accessed 20 Sep 2007.
  34. Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur J Neurol. 2013 Jan;20(1):5-15. doi: 10.1111/j.1468-1331.2012.03866.x. PMID: 23279439
  35. Fox SH, Katzenschlager R, Lim SY, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2011 Oct;26(Suppl 3):S2-S41. doi: 10.1002/mds.23829. PMID: 22021173
  36. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011 Oct;26(Suppl 3):S42-S80. doi: 10.1002/mds.23884. Accessed 5 Mar 2015. PMID: 22021174
  37. Zhao YJ, Wee HL, Chan YH, et al. Progression of Parkinson’s disease as evaluated by Hoenhn and Yahr stage transition times. Mov Disord. 2010 Apr;25(6):710-716. doi: 10.1002/mds.22875. PMID: 20213822
  38. National Institute for Health and Care Excellence . Postural hypotension in adults: fludrocortisone. NICE. https://www.nice.org.uk/advice/esuom20/chapter/key-points-from-the-evidence. 2013.
  39. Sanchez-Ferro A, Benito-Leon J, Gomez-Esteban JC. The management of orthostatic hypotension in parkinson’s disease. Front Neurol. 2013 Jun;4(64). doi: 10.3389/fneur.2013.00064. PMID: 23772219
  40. Dickson DW, Fujishiro H, Orr C, et al. Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat Disord. 2009 Dec;15(Suppl 3):S1-S5. doi: 10.1016/S1353-8020(09)70769-2. PMID: 20082965
  41. Tarsy D. Management of comorbid problems associated with Parkinson disease. UpToDate. www.uptodate.com. 2016 May.
  42. Chahine L, Tarsy D. Management of nonmotor symptoms in Parkinson disease. UpToDate. https://www.uptodate.com. . 12 Oct 2020.
  43. Chou KL. Clinical manifestations of Parkinson disease. UpToDate. https://www.uptodate.com. 17 Nov 2020.
  44. Chou KL. Diagnosis and differential diagnosis of Parkinson disease. UpToDate. https://www.uptodate.com. 11 Aug 2020.
  45. Fleisher J, Tarsy D. Nonpharmacologic management of Parkinson disease. UpToDate. https://www.uptodate.com. 11 Aug 2020.
  46. Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and Movement Disorder Society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2018 Aug;33(8):1248-1266. doi: 10.1002/mds.27372. PMID: 29570866
  47. Grimes D, Fitzpatrick M, Gordon J, et al. Canadian guideline for Parkinson disease. CMAJ. 2019 Sep;191(36):E989-E1004. doi: 10.1503/cmaj.181504. PMID: 31501181
  48. Jankovic J. Etiology and pathogenesis of Parkinson disease. UpToDate. https://www.uptodate.com. 22 Sep 2020.
  49. Keus SHJ, Munneke M, Graziano M, et al. European physiotherapy guideline for Parkinson’s disease. KNGF/ParkinsonNet, the Netherlands. www.parkinsonnet.nl. Dec 2014.
  50. Liang TW, Tarsy D. Medical management of motor fluctuations and dyskinesia in Parkinson disease. UpToDate. https://www.uptodate.com. 17 Sep 2020.
  51. National Institute for Health and Care Excellence (NICE). Parkinson’s disease in adults. NICE. www.nice.org.uk/. 19 Jul 2017.
  52. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015 Oct;30(12):1591-1601. doi: 10.1002/mds.26424. PMID: 10.1002/mds.26424
  53. Rodnitzky RL. Cognitive impairment and dementia in Parkinson disease. UpToDate. https://www.uptodate.com. 15 Apr 2020.
  54. Seppi K, Chaudhuri KR, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease – an evidence-based medicine review. Mov Disord. 2019 Feb;34(2):180-198. doi: 10.1002/mds.27602. PMID: 30653247
  55. Spindler MA, Tarsy D. Initial pharmacologic treatment of Parkinson disease. UpToDate. https://www.uptodate.com. 20 Nov 2020.
Editor's Recommendations
Most Read Articles
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Pearl Toh, 26 Nov 2020
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Audrey Abella, 6 days ago
A pilot telemedicine initiative may be an alternative for facilitating delivery of intravenous iron (IVI) for individuals requiring iron supplementation.